Inadequate femoral artery access causes more than 100,000 people to not address symptomatic aortic stenosis due to insufficient femoral arterial lumen sizes to undergo Transcatheter Aortic Valve Replacement (TAVR). Without treatment, the average survival is only 2-3 years.
We have an investigational closure device for transcaval access to the abdominal aorta. Transcaval access holds great promise for treating those patients who lack an access route and allows placement of the ≥ 16Fr sheath size required for valve delivery.
We have an early feasibility study underway and successfully completed 12 patients.